Implementation of Biopreservation Best Practices to Address a Critical Component of Cell & Gene Therapy Manufacturing Hosted by Cell and Gene Therapy Insights Implementation of best practices in formulation can directly address multiple process bottlenecks including: GMP compliance, minimizing freezing damage, support stability during storage and against transient warming events, support post-thaw stability, and excipient…
Read More Heading to the ISCT Annual Meeting in Melbourne? Bring us your Biopreservation Challenges. If you’re headed to the 2019 ISCT Meeting in Melbourne, join us in BOOTH 84 and learn how we’re strengthening our mission to provide the best cell and gene therapy tools in the industry. Our expanding platform of biopreservation tools now includes…
Read More
According to data provided by the Alliance for Regenerative Medicine, there are nearly 900 companies responsible for more than 1000 industry-sponsored clinical trials within regenerative medicine utilizing advanced therapeutics including cell, gene, and tissue engineered products. Maintaining oversight on these precious therapies, literally vein-to-vein, encompassing a multitude of stakeholders, lengthy timelines, across countries and continents…
Read More
Disease models facilitate understanding the pathogenesis of disease, identification and development of potential interventions and evaluation of new treatments. BioLife Solutions maintains an online, searchable, Evidence Library that contains over 365 articles, abstracts and posters citing Biopreservation efficacy of CryoStor® and HypoThermosol®. Recently added to the Evidence Library, the journal article authored by Xinyue Bai…
Read More
One of the benefits of cryopreserving cells is the flexibility in scheduling for later use that freezing provides. Determining the optimal solution for cryopreservation that consistently results in post-thaw recovery of the greatest number of highly viable, functional cells is crucial. The article by Sara S. Parker et al. published in eNeuro and recently added…
Read More
On November 21, 2018, BioLife’s customer Kolon TissueGene, Inc., a leader in advanced cell and gene therapies, announced that it has dosed its first patient in its pivotal US Phase III clinical trials for Invossa, a cell and gene therapy in development for knee osteoarthritis (OA). “This is an exciting step for Kolon TissueGene as we…
Read More Mesenchymal Stem Cells have been the cell type of interest for the following articles recently entered into BioLife’s growing Evidence library. 1. Sutton, M. T., Kaur, S., Brown, K. S., Skiles, M. L., Folz, M. A., Caplan, A. I. and Bonfield, T. L.. (2018). Anti-Inflammatory Therapeutic Development and Optimization of Umbilical Cord Tissue Derived Mesenchymal…
Read More Revenue increases 79% to a record $5.3 million; achieves net income of $1.2 million On November 8, 2018, BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, reported financial results and operational highlights for the three and nine months ended September 30, 2018. Revenue…
Read More
Temperature Sensitive Gene Therapy Protected by Cloud-Connected Smart Shipper and evo.is Cloud App for Real Time Distribution Visibility and Management On November 5, 2018, BioLife’s JV partner SAVSU Technologies, a leading developer and supplier of precision cloud-connected thermal shipping containers and the most advanced cold chain visibility platform, announced that it is supplying its evo Smart…
Read More
GE Life Sciences recently published the white paper “Workflow for primary human NK cell isolation, xeno-free expansion, harvest, and cryopreservation.” In it, they detail how challenging it is to obtain primary human NK cells at clinically relevant scale, and outline methods for workflow optimization and cryopreservation, utilizing CryoStor CS 10. For additional details or to…
Read More